Improvements in Data Quality Can Boost Efficiency and Reduce Development Costs: A Pharmacometric CRO's Perspective
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.High-quality data is crucial for efficient drug development. Contract research organizations (CROs) spend significant time and resources cleaning sponsor data due to quality issues, highlighting the need for improved data management practices.
Area Of Science
- Pharmacometrics and Drug Development
- Data Management in Clinical Research
Background
- Drug development is a lengthy and expensive process heavily reliant on high-quality data.
- Contract Research Organizations (CROs) play a vital role in managing and analyzing data for drug sponsors.
- Model-Informed Drug Development (MIDD) requires robust and reliable datasets for accurate predictions and decision-making.
Purpose Of The Study
- To assess the impact of data management activities on Model-Informed Drug Development (MIDD) deliverables.
- To evaluate the baseline experience of CROs in assessing sponsor-provided data quality.
- To determine the time and cost associated with preparing analysis-ready datasets.
Main Methods
- A survey was distributed to 44 pharmacometrics professionals across 32 companies offering data management services.
- The anonymous survey consisted of 11 questions (9 multiple-choice, 2 open-ended) focusing on data quality assessment and dataset preparation.
- Responses from 17 participating CROs were analyzed to identify common data quality challenges and time expenditures.
Main Results
- 65% of CROs reported that sponsor-provided data was rarely usable (<10%) due to formatting issues, missing data, and inconsistencies.
- Over 50% identified a lack of clear data definitions and specifications as the primary cause of poor data quality.
- Data cleaning costs range from $750 to $6000 per dataset, requiring 3 to 24 hours of programming time.
Conclusions
- Significant time and financial resources are invested by CROs in rectifying poor-quality sponsor data.
- While automated data quality checks enhance efficiency, they cannot fully address all data integrity issues.
- Improved communication, collaboration, and systematic approaches, including automation and AI, are essential for enhancing data quality in drug development.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
Body:The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...